Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary ...

Airiver Medical, a clinical stage company developing technologies to help patients who suffer from certain respiratory tract ...

As cell and gene therapies (CGTs) continue to advance, they have unique developmental features that may require innovation in a clinical trial setting, the authors of a recent paper explained.

The study is enrolling up to 300 US patients with CRS to evaluate the ESSpand DCB with endoscopic sinus surgery.

Alterity Therapeutics Limited ATHE stock is up during Tuesday’s session as the biotechnology company announced an ...

SpinaFX Medical has received the US Food and Drug Administration (FDA) investigational device exemption (IDE) to study its ...

InspireMD, Inc. announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuroprot ...

The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026 NEWARK, N.J., ...

Apogee Therapeutics advances zumilokibart with a $1.3B Blackstone deal, eyes $82.97 value despite asset risks. Read why APGE stock is a buy.

Ambros Therapeutics, Inc. today announced that the first patient has been dosed in its pivotal CRPS-RISE Phase 3 clinical trial evaluating neridronate versus placebo for the treatment of Complex ...

Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration – – FDA agrees on UMSARS Part I ...